What Is PSA? What the Prostate-Specific Antigen Blood Test Measures

01. PSA Test: Measurement, Calculation and Interpretation

How is a PSA test measured or calculated?

A standard PSA test begins with a blood sample taken from a vein.

The laboratory separates the blood components and uses an immunoassay to detect prostate-specific antigen circulating in the sample.

The most common starting measurement is total PSA.

PSA in the bloodstream exists in more than one molecular form. Some circulates unbound, known as free PSA, while much of the remainder is attached to blood proteins.

A total PSA assay measures the clinically relevant combination of free and complexed forms rather than measuring only one fraction.

The standard PSA concentration itself is measured, not calculated.

Other PSA-related measurements can later be calculated from that result. For example:

• percent-free PSA compares free PSA with total PSA;
• PSA density relates PSA to measured prostate volume;
• PSA velocity describes change in PSA over time;
• and PSA doubling time estimates how long a rising PSA takes to approximately double in selected clinical settings.

These derived values answer different clinical questions and should not be treated as synonyms for the standard PSA blood test.

Which units, thresholds or scoring rules are used for a PSA test?

Serum PSA is usually reported in nanograms per millilitre (ng/mL).

For example, a laboratory result may be reported as 1.2 ng/mL, 3.8 ng/mL or 7.5 ng/mL.

The number is a concentration, not a cancer score.

There is also no single universal threshold that divides all men into “normal” and “cancer” groups.

Historically, 4 ng/mL was often used as a reference value, while many modern screening pathways use other thresholds depending on age, risk and clinical setting.

Current European guidance, for example, commonly uses PSA values around 3 ng/mL as one point at which additional risk assessment may begin in screening pathways, but that does not mean every PSA above 3 ng/mL represents cancer.

Nor does a PSA below a specific threshold guarantee that clinically significant cancer is absent.

02. What Does a PSA Test Measure?

What does a higher or lower PSA test value mean?

A higher PSA means that more prostate-specific antigen is circulating in the blood at the time the sample is taken.

It does not explain why the concentration is higher.

Several biological mechanisms can increase serum PSA.

A larger prostate can contain more PSA-producing tissue. This is one reason benign prostate enlargement can raise PSA without cancer.

Inflammation can disrupt normal barriers between prostate glandular tissue and the bloodstream, allowing more PSA to enter the circulation.

Prostate cancer can also increase serum PSA through altered glandular architecture and increased release of PSA into blood.

A lower PSA usually indicates that less PSA is circulating, but this also requires context.

A smaller prostate may naturally produce less total PSA. Medicines that reduce prostate tissue can lower PSA. Testosterone and androgen activity also influence PSA production.

Therefore, high and low PSA values are measurements of a biomarker, not diagnoses by themselves.

Which factors can change or distort a PSA test?

PSA varies naturally within the same person and between laboratories.

Current European guidance notes that intra-individual PSA variation can be approximately ±15%, while laboratory and assay differences can introduce additional variation.

That means a modest change between two PSA results does not always represent a true biological change in the prostate.

Important factors include:

The effects of finasteride and dutasteride are particularly important.

These 5-alpha-reductase inhibitors shrink androgen-dependent prostate tissue and typically lower circulating PSA by approximately 50% after sustained treatment.

That does not make PSA useless. It means the clinician must know that the patient is taking the drug and interpret the value and subsequent trend accordingly.

03. PSA Test: Reference Values, Modifiers and Limitations

How should a PSA test be interpreted alongside other prostate findings?

PSA interpretation works best when the blood value is combined with the clinical picture.

Important information can include:

• the patient’s age;
• previous PSA results;
• how quickly the value has changed;
• measured prostate volume;
• family history of prostate cancer;
• known inherited cancer-risk variants;
• current medications;
• symptoms of infection or inflammation;
• recent urinary retention or prostate procedures;
• digital rectal examination findings;
• and, when appropriate, prostate MRI findings.

Prostate volume is particularly relevant because the same PSA concentration can have a different interpretation in a small gland than in a very large gland.

The measurement methods behind prostate size are explained in How Prostate Volume Is Measured.

PSA density can later combine the two measurements mathematically.

What can a PSA test not diagnose or prove by itself?

A PSA result cannot by itself establish:

• whether prostate cancer is present;
• whether an elevated value is caused by BPH, inflammation or cancer;
• the location of a suspicious prostate lesion;
• the Gleason pattern or Grade Group of a cancer;
• whether cancer has extended beyond the prostate;
• whether cancer has spread to lymph nodes or bone;
• or whether an individual patient needs treatment.

A PSA test also does not directly measure urinary obstruction.

A man with BPH may have an elevated PSA because his prostate is larger, but the PSA value cannot tell how narrow his urinary channel is or how strongly his bladder contracts.

Similarly, prostate cancer can be present in a man who has no urinary symptoms.

04. How Does a PSA Test Affect the Next Clinical Decision?

When should a PSA test be repeated, confirmed or combined with another test?

Repeat testing can be important when a PSA result is unexpectedly elevated.

Current European guidance notes that PSA has meaningful biological variability. Among men with PSA below 10 ng/mL, substantial differences can occur between two measurements even without a major change in disease.

For asymptomatic men with an initial PSA between approximately 3 and 10 ng/mL and no suspicious finding on prostate palpation, current EAU guidance recommends repeating PSA before moving to further investigation.

The guideline describes a repeat measurement after approximately four weeks in that particular setting.

The repeat test should ideally be performed:

• in the same laboratory;
• using the same assay;
• without an active urinary tract infection;
• without recent prostate manipulation;
• and under standardized conditions regarding recent ejaculation.

This four-week interval should not be applied blindly to every PSA result. Recent biopsy, significant infection and other clinical circumstances can require a different interval.

How does a PSA test change the next step in prostate evaluation?

The PSA result changes the probability assessment rather than delivering a yes-or-no diagnosis.

A lower-risk result may lead to continued monitoring at an interval appropriate to the patient’s age, baseline PSA, health and risk factors.

An unexpectedly elevated result may first lead to confirmation and evaluation of temporary causes.

A persistent or concerning PSA may then be interpreted alongside:

• prostate volume and PSA density;
• percent-free PSA or other selected biomarkers;
• family history and inherited risk;
• digital rectal examination;
• validated prostate-cancer risk calculators;
• and prostate MRI.

When the combined findings indicate sufficient risk of clinically significant prostate cancer, prostate biopsy may be recommended to obtain tissue for pathological diagnosis.

Why should PSA trends be interpreted carefully?

Repeated PSA measurements can reveal whether the value is broadly stable, fluctuating or persistently increasing.

That longitudinal information is often more useful than seeing one isolated number.

However, a rising PSA does not automatically mean cancer progression.

A changing trend can still be influenced by gland growth, inflammation, laboratory variability, medications and other factors.

For the same reason, current prostate-cancer early-detection guidance does not recommend using PSA velocity alone as the sole reason to proceed to imaging or biopsy.

What should patients know before having a PSA blood test?

A useful PSA discussion includes more than simply ordering the blood test.

Patients should tell the clinician about:

• previous PSA results;
• finasteride or dutasteride use;
• recent urinary infection or prostatitis;
• recent urinary retention;
• a recent prostate biopsy or urinary procedure;
• family history of prostate cancer;
• known inherited cancer-risk variants;
• and previous prostate treatment.

They should also understand in advance that an abnormal PSA does not automatically mean cancer and that additional testing may be needed before a clear explanation is available.

For the complete PSA testing pathway, return to PSA Testing and Prostate Screening.